Gabriela Schmajuk, MD, MS

Associate Professor

Dr. Schmajuk is Chief of Rheumatology at the San Francisco VA Health Care System and an Associate Professor in the Division of Rheumatology, Department of Medicine at UCSF. She received her undergraduate degree from Harvard, her MD from the University of Pennsylvania, and her Masters in Epidemiology from Stanford. She joined the faculty after completing internal medicine residency at Brigham and Women's Hospital and fellowship in rheumatology at Stanford. She practices in the SFVA rheumatology clinic.

Dr. Schmajuk's research focuses on quality of care and patient safety in patients with rheumatic diseases. She co-directs the UCSF Rheumatology Quality and Informatics Lab (quil.ucsf.edu), an interdisciplinary group that uses health services research, informatics, and implementation science to inform national health care improvement initiatives. Her work specifically highlights and aims to attenuate disparities in care across sex, race/ethnicity, socioeconomic status, and health literacy. She uses a variety of "big data" sources, including Medicare and EHR data from the VA and the he American College of Rheumatology’s RISE registry, which aggregates and analyzes data from rheumatology practices around the country. She also has projects to use Health-IT to integrate patient reported outcomes into clinical encounters in rheumatology.

Dr. Schmajuk has served as PI of grants from the NIH/NIAMS, AHRQ, and VA HSR&D, and has earned several honors and awards for her work, including the Ephraim Engleman Award for Arthritis Research, and the J.V. Satterfield Excellence in Rheumatology Research Award from the Arthritis Foundation.
Education
Internal Medicine, - , Brigham and Women's Hospital
A.B., - Biochemical Sciences, Harvard
Rheumatology, - , Stanford Hospital
MSc, - Epidemiology, Stanford University
MD, - Medicine, University of Pennsylvania
Websites
Publications
  1. Quality of care for patients with SLE: data from the American College of Rheumatology's RISE registry.
  2. Rheumatology Informatics System for Effectiveness (RISE) Practices See Significant Gains in Rheumatoid Arthritis Quality Measures.
  3. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.
  4. Reweighting to address nonparticipation and missing data bias in a longitudinal electronic health record study.
  5. Mortality among Hospitalized Individuals with Systemic Lupus Erythematosus in the United States between 2006 and 2016.
  6. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
  7. SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events.
  8. Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes.
  9. Patient and clinician perspectives on a patient-facing dashboard that visualizes patient reported outcomes in rheumatoid arthritis.
  10. RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.
  11. Three Quality Improvement Initiatives Improved Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results from an Interrupted Time Series Study.
  12. Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.
  13. Quality Measures and Quality Improvement Initiatives in Osteoporosis-an Update.
  14. Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review.
  15. Prevalence of Arthritis and Rheumatoid Arthritis in Coal Mining Counties of the U.S.
  16. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
  17. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
  18. Effects of language, insurance and race/ethnicity on measurement properties of the PROMIS Physical Function Short Form 10a in rheumatoid arthritis.
  19. Differences in Longitudinal Disease Activity Between Research Cohort and Noncohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data.
  20. Differences in Longitudinal Disease Activity Between Research Cohort and Noncohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data.
  21. Increased risk of ischemic stroke in systemic sclerosis: a national cohort study of US veterans.
  22. Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis.
  23. Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.
  24. Automated and flexible identification of complex disease: building a model for systemic lupus erythematosus using noisy labeling.
  25. Obesity Independently Associates with Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus.
  26. Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates.
  27. Editorial: The Evolving Art and Science of American College of Rheumatology Guidelines.
  28. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
  29. Further Lessons in Pneumocystis Pneumonia Prophylaxis.
  30. Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data.
  31. "Am I OK?" using human centered design to empower rheumatoid arthritis patients through patient reported outcomes.
  32. Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus.
  33. OP0325 Effect of three health it interventions on ra disease activity score documentation in an academic rheumatology clinic.
  34. Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study.
  35. Correction to: Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
  36. The impact of smoking on disease measures in rheumatoid arthritis: the need for appropriate adjustment of time-varying confounding.
  37. Using Spatial and Temporal Mapping to Identify Nosocomial Disease Transmission of Clostridium difficile.
  38. Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis.
  39. Leveraging the electronic health record to improve quality and safety in rheumatology.
  40. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
  41. Endoscopy is of low yield in the identification of gastrointestinal neoplasia in patients with dermatomyositis: A cross-sectional study.
  42. Variations in Radiographic Procedure Use for Medicare Patients With Rheumatoid Arthritis.
  43. Reply.
  44. Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab.
  45. Is frailty a relevant concept in SLE?
  46. Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures.
  47. Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures.
  48. Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic.
  49. THU0096 Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis.
  50. Poverty, Depression, or Lost in Translation? Ethnic and Language Variation in Patient-Reported Outcomes in Rheumatoid Arthritis.
  51. National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia.
  52. Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis.
  53. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
  54. Efficiency Gains for Rheumatology Consultation Using a Novel Electronic Referral System in a Safety-Net Health Setting.
  55. Muscle Strength and Changes in Physical Function in Women With Systemic Lupus Erythematosus.
  56. Factors associated with access to rheumatologists for Medicare patients.
  57. SAT0415 Performance of Anti-Nuclear Antibodies (ANA) for Classifying Systemic Lupus Erythematosus (SLE): A Systematic Literature Review and Meta-Regression of Diagnostic Data.
  58. A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis.
  59. Interactions between patients, providers, and health systems and technical quality of care.
  60. Using medicare data to understand health care value--reply.
  61. Muscle strength, muscle mass, and physical disability in women with systemic lupus erythematosus.
  62. CRB2 mutations produce a phenotype resembling congenital nephrosis, Finnish type, with cerebral ventriculomegaly and raised alpha-fetoprotein.
  63. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
  64. Using Medicare data to understand low-value health care: the case of intra-articular hyaluronic acid injections.
  65. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.
  66. Proteome-wide analysis and CXCL4 in systemic sclerosis.
  67. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study.
  68. Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.
  69. Missed opportunities for depression screening in patients with arthritis in the United States.
  70. Underestimation of the reliability of codes for rheumatoid arthritis within administrative data: comment on the article by Ng et al.
  71. Transitional care challenges of rehospitalized veterans: listening to patients and providers.
  72. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.
  73. Poor knowledge of methotrexate associated with older age and limited English-language proficiency in a diverse rheumatoid arthritis cohort.
  74. Sex differences in assessment of obesity in rheumatoid arthritis.
  75. Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care.
  76. An Overview.
  77. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.
  78. Systematic review of the literature informing the systemic lupus erythematosus indicators project: reproductive health care quality indicators.
  79. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?
  80. Drug monitoring in systemic lupus erythematosus: a systematic review.
  81. Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.
  82. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.
  83. Arthritis: in the eye of the beholder?
  84. A caution on interpreting odds ratios.
  85. First report of idiopathic granulomatous mastitis treated with methotrexate monotherapy.
  86. Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients.
  87. A quality indicator set for systemic lupus erythematosus.
  88. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
  89. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake.